CERo Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

Stocks . USA . 
Stock . CERo Therapeutics Holdings
CEROW Stock   0.01  0  14.29%   
CERo Therapeutics financial indicator trend analysis is way more than just evaluating CERo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CERo Therapeutics is a good investment. Please check the relationship between CERo Therapeutics Ev To Free Cash Flow and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CERo Therapeutics Ev To Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between CERo Therapeutics' Ev To Free Cash Flow and Free Cash Flow Yield is -0.45. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of CERo Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of CERo Therapeutics' Ev To Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of CERo Therapeutics Holdings are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Ev To Free Cash Flow i.e., CERo Therapeutics' Ev To Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.45
Relationship DirectionNegative 
Relationship StrengthVery Weak

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.
Most indicators from CERo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CERo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Selling General Administrative is likely to drop to 2,748 in 2024. Enterprise Value Over EBITDA is likely to drop to -31.51 in 2024
 2010 2022 2023 2024 (projected)
Interest Income986.7K142.1K127.9K121.5K
Net Interest Income986.7K142.1K127.9K121.5K

CERo Therapeutics fundamental ratios Correlations

Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Shares Outstanding
Non Current Liabilities Total
Capital Lease Obligations
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Capital Stock
Net Working Capital
Total Assets
0.95-0.44-0.621.00.95-0.980.470.97-0.89-0.410.990.80.98-0.410.98-0.790.99-0.850.53-0.880.96-0.87-0.63-0.850.97
Short Long Term Debt Total
0.95-0.69-0.830.970.83-0.990.710.86-0.7-0.670.980.610.99-0.670.98-0.60.91-0.640.24-0.981.0-0.7-0.84-0.660.98
Other Current Liab
-0.44-0.690.98-0.49-0.180.61-1.0-0.22-0.031.0-0.530.1-0.591.0-0.57-0.1-0.34-0.110.540.81-0.65-0.010.97-0.06-0.58
Total Current Liabilities
-0.62-0.830.98-0.67-0.390.77-0.98-0.430.190.97-0.71-0.11-0.750.97-0.740.11-0.540.110.340.91-0.80.211.00.16-0.74
Total Stockholder Equity
1.00.97-0.49-0.670.94-0.990.520.96-0.86-0.461.00.770.99-0.460.99-0.760.99-0.810.47-0.910.98-0.84-0.68-0.820.98
Property Plant And Equipment Net
0.950.83-0.18-0.390.94-0.880.210.99-0.97-0.150.920.940.89-0.150.88-0.830.98-0.950.72-0.730.87-0.91-0.4-0.90.85
Current Deferred Revenue
-0.98-0.990.610.77-0.99-0.88-0.63-0.910.780.58-1.0-0.68-1.00.58-0.990.68-0.950.72-0.350.96-1.00.770.770.74-0.99
Net Debt
0.470.71-1.0-0.980.520.21-0.630.250.0-1.00.56-0.070.62-1.00.60.070.370.08-0.51-0.820.67-0.02-0.980.030.61
Retained Earnings
0.970.86-0.22-0.430.960.99-0.910.25-0.97-0.190.940.910.91-0.190.92-0.860.99-0.950.71-0.750.88-0.93-0.44-0.920.89
Accounts Payable
-0.89-0.7-0.030.19-0.86-0.970.780.0-0.97-0.06-0.83-0.95-0.79-0.06-0.80.92-0.931.0-0.860.57-0.740.970.20.97-0.77
Cash
-0.41-0.671.00.97-0.46-0.150.58-1.0-0.19-0.06-0.50.13-0.571.0-0.54-0.13-0.31-0.140.560.79-0.63-0.040.96-0.09-0.56
Non Current Assets Total
0.990.98-0.53-0.711.00.92-1.00.560.94-0.83-0.50.741.0-0.50.99-0.730.98-0.780.43-0.930.99-0.82-0.71-0.790.98
Non Currrent Assets Other
0.80.610.1-0.110.770.94-0.68-0.070.91-0.950.130.740.690.130.68-0.760.86-0.950.84-0.50.67-0.84-0.12-0.840.63
Other Assets
0.980.99-0.59-0.750.990.89-1.00.620.91-0.79-0.571.00.69-0.571.0-0.70.96-0.740.36-0.950.99-0.78-0.76-0.750.99
Cash And Short Term Investments
-0.41-0.671.00.97-0.46-0.150.58-1.0-0.19-0.061.0-0.50.13-0.57-0.54-0.13-0.31-0.140.560.79-0.63-0.040.96-0.09-0.56
Common Stock Shares Outstanding
0.980.98-0.57-0.740.990.88-0.990.60.92-0.8-0.540.990.681.0-0.54-0.740.96-0.750.39-0.930.98-0.81-0.74-0.781.0
Non Current Liabilities Total
-0.79-0.6-0.10.11-0.76-0.830.680.07-0.860.92-0.13-0.73-0.76-0.7-0.13-0.74-0.830.92-0.840.44-0.610.990.120.99-0.74
Capital Lease Obligations
0.990.91-0.34-0.540.990.98-0.950.370.99-0.93-0.310.980.860.96-0.310.96-0.83-0.90.61-0.830.93-0.9-0.55-0.890.94
Other Current Assets
-0.85-0.64-0.110.11-0.81-0.950.720.08-0.951.0-0.14-0.78-0.95-0.74-0.14-0.750.92-0.9-0.90.5-0.680.960.120.97-0.72
Other Stockholder Equity
0.530.240.540.340.470.72-0.35-0.510.71-0.860.560.430.840.360.560.39-0.840.61-0.9-0.070.29-0.830.33-0.860.36
Total Liab
-0.88-0.980.810.91-0.91-0.730.96-0.82-0.750.570.79-0.93-0.5-0.950.79-0.930.44-0.830.5-0.07-0.970.550.920.51-0.92
Net Invested Capital
0.961.0-0.65-0.80.980.87-1.00.670.88-0.74-0.630.990.670.99-0.630.98-0.610.93-0.680.29-0.97-0.71-0.81-0.680.97
Property Plant And Equipment Gross
-0.87-0.7-0.010.21-0.84-0.910.77-0.02-0.930.97-0.04-0.82-0.84-0.78-0.04-0.810.99-0.90.96-0.830.55-0.710.221.0-0.81
Total Current Assets
-0.63-0.840.971.0-0.68-0.40.77-0.98-0.440.20.96-0.71-0.12-0.760.96-0.740.12-0.550.120.330.92-0.810.220.17-0.75
Capital Stock
-0.85-0.66-0.060.16-0.82-0.90.740.03-0.920.97-0.09-0.79-0.84-0.75-0.09-0.780.99-0.890.97-0.860.51-0.681.00.17-0.77
Net Working Capital
0.970.98-0.58-0.740.980.85-0.990.610.89-0.77-0.560.980.630.99-0.561.0-0.740.94-0.720.36-0.920.97-0.81-0.75-0.77
Click cells to compare fundamentals

CERo Therapeutics Account Relationship Matchups

High Positive Relationship

Total Stockholder Equity
+ 1.0
Total Assets
Net Invested Capital
+ 1.0
Short Long Term Debt Total
Cash
+ 1.0
Other Current Liab
Cash And Short Term Investments
+ 1.0
Other Current Liab
Total Current Assets
+ 1.0
Total Current Liabilities
Non Current Assets Total
+ 1.0
Total Stockholder Equity

High Negative Relationship

Cash And Short Term Investments
- 1.0
Net Debt
Cash
- 1.0
Net Debt
Net Invested Capital
- 1.0
Current Deferred Revenue
Other Assets
- 1.0
Current Deferred Revenue
Non Current Assets Total
- 1.0
Current Deferred Revenue
Net Debt
- 1.0
Other Current Liab

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for CERo Stock Analysis

When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY